Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Message From the Editors to Our Reviewers: 2025.

Neurology. Clinical practice·2026

Same author

Differential Progression of Neuroinflammation in Patients with Isolated Rapid-Eye-Movement Sleep Behavior Disorder.

Movement disorders : official journal of the Movement Disorder Society·2026

Same author

Positron emission tomography imaging of the cholinergic system in parkinsonian tremor.

Parkinsonism & related disorders·2026

Same author

Diffusion kurtosis imaging detects cortical microstructural alterations in amyloid-positive MCI patients.

Frontiers in dementia·2026

Same author

Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.

Nature medicine·2025

Same author

[<sup>11</sup>C](R)-PK11195 Positron Emission Tomography Imaging of Skull Inflammation in Isolated Rapid-Eye-Movement Sleep Behavior Disorder.

Movement disorders : official journal of the Movement Disorder Society·2025

Search research articles

Related Experiment Video

Updated: Jul 16, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

Imaging non-dopaminergic function in Parkinson's disease.

David J Brooks¹

¹MRC Clinical Sciences Centre and Division of Neuroscience and Mental Health, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK. david.brooks@csc.mrc.ac.uk

Molecular Imaging and Biology

|March 7, 2007

Summary

Parkinson's disease (PD) affects multiple neurotransmitter systems beyond dopamine. This review explores imaging techniques for non-dopaminergic systems and microglial activation in PD.

More Related Videos

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Published on: June 17, 2013

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Related Experiment Videos

Last Updated: Jul 16, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Published on: June 17, 2013

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Area of Science:

Neuroscience
Neurology
Medical Imaging

Background:

Parkinson's disease (PD) involves degeneration of dopaminergic, cholinergic, noradrenergic, and serotonergic systems.
Neuronal loss in PD is linked to microglial activation, a process whose role in disease progression is unclear.

Purpose of the Study:

To review current findings on non-dopaminergic system function in PD.
To discuss the role of microglial activation in Parkinson's disease pathogenesis.
To correlate neuroimaging of these systems with motor and non-motor symptoms.

Main Methods:

Review of current literature on neuroimaging techniques.
Analysis of positron emission tomography (PET) and single photon emission computed tomography (SPECT) studies.
Correlation of imaging data with clinical symptomatology.

Main Results:

Non-dopaminergic systems can be effectively imaged in PD.
Imaging findings correlate with both motor and non-motor symptoms.
Microglial activation is a feature of neuronal loss in PD, but its causative role requires further investigation.

Conclusions:

Imaging of non-dopaminergic systems provides valuable insights into PD.
The precise role of microglia in driving PD progression remains an area for future research.
Understanding these systems is crucial for developing comprehensive therapeutic strategies.